Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01779505 · ClinicalTrials.gov registry record · Phase 1

A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults

A Phase 1 study of Healthy Volunteers, sponsored by Gilead Sciences.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT01779505: Completed Phase 1 study of Healthy Volunteers, sponsored by Gilead Sciences.

NCT01779505 is a Phase 1 study of Healthy Volunteers that has completed, run by Gilead Sciences. The registered enrollment target is 60 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01779505, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This trial will be test the safety, tolerability, and immunogenicity of GS-4774 (GI-13020) in various doses and dosing regimens in healthy adults at one center in the US. Subjects will be enrolled into 3 arms using a dose escalation scheme and randomized into one of two dosing regimen cohorts. There will be 10 subjects per arm/cohort (total of 60 subjects to achieve 48 evaluable subjects enrolled), with study completion in 9-12 months.

Primary Outcome

Frequency of serious adverse events Frequency and severity of common non-serious adverse events Frequency of discontinuations of therapy due to adverse events Common laboratory assessments (chemistry, hematology, urinalysis) Dose Limiting Toxicities

Conditions Studied

Interventions

  • BIOLOGICAL GS-4774

Study Locations (1)

Arizona

  • Celerion - Phoenix

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2013-01
Est. Completion 2013-08
Phase Phase 1
Gilead Sciences

504 total trials

What the finished NCT01779505 record still lists

NCT01779505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which GS-4774 is the first listed.

NCT01779505 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT01779505 about?

NCT01779505 is a clinical study titled "A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults". This trial will be test the safety, tolerability, and immunogenicity of GS-4774 (GI-13020) in various doses and dosing regimens in healthy adults at one center in the US. Subjects will be enrolled into 3 arms using a dose escalation scheme and randomized into one of two dosing regimen cohorts. There...

What is the current status of trial NCT01779505?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2013-01. Estimated completion is 2013-08.

What conditions does trial NCT01779505 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT01779505?

The interventions under investigation include: GS-4774 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01779505?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01779505 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01779505's enrollment target sits among peer trials

60 109th of 283 higher than 163 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01779505, the US trial registry maintained by the National Library of Medicine. NCT01779505 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.